Enforcement Report - Week of March 30, 2022
Enforcement Report - Week of February 23, 2022
PARSIPPANY, N.J., Feb. 3, 2022 /PRNewswire/ -- Pharmaceutical Associates, Inc. (PAI) announces that it has acquired all of the generic and branded US marketing authorizations from Teligent Inc. (Teligent) for an undisclosed amount.
LONDON, Jan. 17, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that it has agreed to acquire the Canadian assets of Teligent Inc. (Teligent) for $45.75 million. The transaction is expected to be completed before the end of the first quarter of 2022.
Enforcement Report - Week of January 5, 2022
Enforcement Report - Week of December 22, 2021
Roche Holdings AG RHHBY -2.51% (Get Free Alerts for RHHBY) announced results from the Phase 3 POLARIX study of Polivy (polatuzumab vedotin) with MabThera/Rituxan (rituximab) and the chemotherapy regimen R-CHOP. Data were presented at the American Society of Hematology (ASH) Annual Meeting and Exposition.
(RTTNews) - Buena, New Jersey-based Teligent Pharma, Inc. is recalling two lots of Lidocaine HCl Topical Solution USP 4%, 50ml to the user level due to super potency, the U.S. Food and Drug Administration said.
Teligent Pharma Issues Worldwide Voluntary Recall of Lidocaine HCl Topical Solution USP 4%
Enforcement Report - Week of December 1, 2021